The failure of single-pathway drugs to meaningfully reverse liver scarring in metabolic dysfunction-associated steatohepatitis (MASH) has forced a strategic pivot toward combination therapy approaches that could benefit millions with this obesity-linked liver disease. Current monotherapies targeting individual mechanisms show only modest improvements in the hallmark liver fibrosis that drives MASH progression.
Researchers are now exploring dual-drug regimens that simultaneously attack different disease mechanisms. Promising combinations include thyroid hormone receptor-beta agonists paired with acetyl-CoA carboxylase inhibitors to directly target liver fat accumulation and inflammation. Another approach combines GLP-1 receptor agonists—already proven for weight loss—with fibroblast growth factor-21 analogues to address both systemic metabolism and liver-specific pathways. Strategic drug pairings like diacylglycerol O-acyltransferase 2 inhibitors combined with ACC inhibitors may actually reduce side effects by leveraging complementary mechanisms.
This combination strategy represents a fundamental shift from the reductionist single-target approach that has dominated MASH drug development for decades. The multifactorial nature of MASH—involving insulin resistance, lipid metabolism dysfunction, and inflammatory cascades—suggests that effective treatment may require simultaneously modulating multiple pathways rather than hoping one mechanism can reverse complex liver pathology. However, combination therapies introduce new challenges around drug interactions, dosing optimization, and regulatory approval pathways. The success of this approach could establish a new paradigm for treating metabolic liver diseases where single mechanisms have repeatedly failed to deliver clinically meaningful outcomes.